Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Introduction: We discuss chemical conjugation strategies for antibody-drug conjugates
(ADCs) from an industrial perspective and compare three promising chemical conjugation …

The site-directed chemical conjugation of antibodies remains an area of great interest and
active efforts within the antibody–drug conjugate (ADC) community. We previously reported …

Continuous flow reactors enable chemical reactions to occur within shielded pipes and
tubes. This synthetic process is considered to overcome some limitations of commonly used …

Antibody–drug conjugates (ADCs) are biopharmaceuticals produced by chemically linking
small molecules (payloads) to antibodies that possess specific affinity for the target cell. The …

In the past two decades, antibody–drug conjugates have gained increasing attention
because they expand the therapeutic index when compared with that of traditional …

Abstract Currently, although> 10 antibody− drug conjugates (ADCs) are available in the
market, most of them (10 ADCs) have broad drug distribution, thereby potentially limiting …

To overcome a lack of selectivity during the chemical modification of native non-engineered
antibodies, we have developed a technology platform termed “AJICAP” for the site-specific …

Aim: Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate
(ADC) field was conducted. Methods: Four different analytical methods [AlogP calculation …

Antibody based drugs, including IgG monoclonal antibodies, are an expanding class of
therapeutics widely employed to treat cancer, autoimmune and infectious diseases. IgG …